JP2019520405A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520405A5
JP2019520405A5 JP2019500483A JP2019500483A JP2019520405A5 JP 2019520405 A5 JP2019520405 A5 JP 2019520405A5 JP 2019500483 A JP2019500483 A JP 2019500483A JP 2019500483 A JP2019500483 A JP 2019500483A JP 2019520405 A5 JP2019520405 A5 JP 2019520405A5
Authority
JP
Japan
Prior art keywords
associated virus
adeno
recombinant adeno
vector
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019500483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520405A (ja
JP7493334B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/040735 external-priority patent/WO2018009553A1/en
Publication of JP2019520405A publication Critical patent/JP2019520405A/ja
Publication of JP2019520405A5 publication Critical patent/JP2019520405A5/ja
Priority to JP2022023711A priority Critical patent/JP2022084594A/ja
Application granted granted Critical
Publication of JP7493334B2 publication Critical patent/JP7493334B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019500483A 2016-07-05 2017-07-05 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達 Active JP7493334B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022023711A JP2022084594A (ja) 2016-07-05 2022-02-18 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662358541P 2016-07-05 2016-07-05
US62/358,541 2016-07-05
US201762511629P 2017-05-26 2017-05-26
US62/511,629 2017-05-26
PCT/US2017/040735 WO2018009553A1 (en) 2016-07-05 2017-07-05 Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022023711A Division JP2022084594A (ja) 2016-07-05 2022-02-18 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達

Publications (3)

Publication Number Publication Date
JP2019520405A JP2019520405A (ja) 2019-07-18
JP2019520405A5 true JP2019520405A5 (enExample) 2020-08-13
JP7493334B2 JP7493334B2 (ja) 2024-05-31

Family

ID=60912274

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019500483A Active JP7493334B2 (ja) 2016-07-05 2017-07-05 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達
JP2022023711A Pending JP2022084594A (ja) 2016-07-05 2022-02-18 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022023711A Pending JP2022084594A (ja) 2016-07-05 2022-02-18 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達

Country Status (7)

Country Link
US (2) US20190240353A1 (enExample)
EP (1) EP3481433B1 (enExample)
JP (2) JP7493334B2 (enExample)
KR (1) KR20190096329A (enExample)
CN (1) CN110177577A (enExample)
MX (1) MX2019000221A (enExample)
WO (1) WO2018009553A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3288379T3 (pl) 2015-05-01 2022-03-07 Onl Therapeutics, Inc. Kompozycje peptydowe i sposoby stosowania
EP3768301A4 (en) * 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
US10862211B2 (en) * 2018-08-21 2020-12-08 Htc Corporation Integrated antenna structure
US10818758B2 (en) 2018-11-16 2020-10-27 Asm Ip Holding B.V. Methods for forming a metal silicate film on a substrate in a reaction chamber and related semiconductor device structures
WO2023048529A1 (ko) * 2021-09-27 2023-03-30 (주) 씨드모젠 Aav2-f11 단백질을 유효성분으로 포함하는 녹내장 예방 또는 치료용 조성물
US20250163131A1 (en) * 2021-12-27 2025-05-22 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
WO2023192450A1 (en) * 2022-03-30 2023-10-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated virus vectors for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6962815B2 (en) * 2001-01-05 2005-11-08 Children's Hopital Inc. AAV2 vectors and methods
SG168422A1 (en) 2001-11-13 2011-02-28 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
GB0820262D0 (en) * 2008-11-05 2008-12-10 Tmo Renewables Ltd Microorganisms
WO2012061045A2 (en) * 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EP2586793A1 (en) * 2011-10-27 2013-05-01 Centre National de la Recherche Scientifique Chimeric molecule involving oligomerized FasL extracellular domain
US9873747B2 (en) * 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
IL293294B2 (en) * 2013-03-15 2023-04-01 Univ North Carolina Chapel Hill Methods and compounds for ligation of paired aav glycan vectors
US20160256571A1 (en) * 2013-09-30 2016-09-08 Sanofi Invention

Similar Documents

Publication Publication Date Title
JP2019520405A5 (enExample)
JP2019089787A5 (enExample)
JP2018520997A5 (enExample)
JP2019537437A5 (enExample)
MX2020005451A (es) Capsides variantes de virus adenoasociados y uso para inhibir la angiogenesis.
PH12018502387A1 (en) Adeno-associated virus variant capsids and methods of use thereof
JP2020028308A5 (enExample)
WO2018022905A3 (en) Adeno-associated virus virions with variant capsid and methods of use thereof
WO2019060454A3 (en) Adeno-associated virus variant capsids and methods of use thereof
HRP20211024T4 (hr) Aav vektori za gensku terapiju mrežnice i cns-a
JP2017536116A5 (enExample)
JP2016538885A5 (enExample)
JP2019523648A5 (enExample)
JP2015523379A5 (enExample)
RU2019100525A (ru) Векторная система на основе аденоассоциированного вируса
JP2014512171A5 (enExample)
AR076796A1 (es) Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento.
JP2015501156A5 (enExample)
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
JP2017538401A5 (enExample)
JP2019530462A5 (enExample)
WO2012145601A3 (en) Adeno-associated virus virions with variant capsid and methods of use thereof
JP2018516869A5 (enExample)
US20250099554A1 (en) Compositions and methods of fas inhibition
RU2020111038A (ru) Аденоассоциированные вирусные векторы для лечения миоцилиновой (myoc) глаукомы